Autoimmune Diseases  >>  Tarpeyo (budesonide)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tarpeyo (budesonide) / Calliditas, Stada
NCT00767221: Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study

Completed
2
20
Europe
Budesonide, Nefecon, PL-56 (topical acting, anti-inflammatory agent)
Calliditas Therapeutics AB, Archimedes Development Ltd
IGA Nephropathy
11/08
11/08
NEFIGAN, NCT01738035 / 2012-001923-11: The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease

Completed
2
150
Europe
NEFECON, Budesonide modified-released capsules (4 mg/capsule), Placebo
Calliditas Therapeutics AB
Primary IgA Nephropathy
06/15
09/15

Download Options